Form 4: Centessa Pharmaceuticals General Counsel Executes Options and Sells Shares Under Pre-Arranged Plan

Centessa Pharmaceuticals plc's General Counsel, Iqbal J. Hussain, exercised stock options and subsequently sold a portion of the acquired shares on June 24, 2025, as part of a pre-established Rule 10b5-1 trading plan.

Summary

• Iqbal J. Hussain, General Counsel of Centessa Pharmaceuticals plc, engaged in two transactions on June 24, 2025.
• Mr. Hussain acquired 12,000 Ordinary Shares by exercising stock options at a price of $5.84 per share.
• Immediately following the option exercise, Mr. Hussain sold 12,000 Ordinary Shares at a weighted average price of $14.0182 per share, with individual sales ranging from $14.00 to $14.08.
• The sale was conducted pursuant to a Rule 10b5-1 trading plan adopted by Mr. Hussain on September 14, 2024.
• After these transactions, Mr. Hussain directly beneficially owns 105,386 Ordinary Shares.
• Additionally, 5,500 Ordinary Shares are indirectly beneficially owned by his spouse.
• Mr. Hussain retains 291,559 share options (right to buy) with an exercise price of $5.84, which vest according to a schedule that began on February 19, 2022, and expire on February 19, 2031.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While it involves insider selling, it was pre-planned under a 10b5-1 plan, which reduces concerns about negative sentiment. The executive also realized a substantial profit, indicating a successful personal financial outcome from their equity compensation.

Positives

• The General Counsel realized a significant profit from the option exercise and subsequent sale, with shares acquired at $5.84 and sold at an average of $14.0182.
• The transaction was executed under a Rule 10b5-1 trading plan, indicating a pre-scheduled, non-discretionary sale, which often mitigates negative perceptions associated with insider selling.

Negatives

• The sale of shares by a high-ranking executive, even if pre-planned, could be interpreted by some investors as a lack of confidence in the company's future prospects, although the 10b5-1 plan lessens this concern.

Risks

• While the sale was pre-planned, significant insider selling, even routine, can sometimes lead to negative market sentiment if not properly understood by investors.

Future Outlook

This Form 4 filing primarily reports past insider transactions and does not contain forward-looking statements or guidance regarding the company's future performance or strategic outlook.

Industry Context

This filing is a routine disclosure of insider trading activity, common across all publicly traded companies, particularly for executives managing their equity compensation through pre-arranged trading plans like Rule 10b5-1. It reflects an individual executive's financial planning rather than a specific industry trend.

Stakeholder Impact

• Shareholders: May observe the executive's profit-taking, but the 10b5-1 plan mitigates concerns about a lack of confidence. The remaining significant option holdings suggest continued alignment with shareholder interests.
• Employees: No direct impact mentioned.

Key Dates

Keywords

Centessa Pharmaceuticals, CNTA, Form 4, Insider Trading, Stock Options, Rule 10b5-1, General Counsel, Share Sale, Equity Compensation